Skip to content

Joseph Peill

16 papers in the library · 261 citations · publishing 2022-2026

Papers

Sort Most recent Most cited

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

bioRxiv (Cold Spring Harbor Laboratory) October 13, 2026 Claudio Agnorelli, Joseph Peill, Danielle Kurtin et al. preprint

Neuroplasticity, the brain's capacity to reorganise its structure and function, is a transdiagnostic feature across psychiatric and neurodegenerative diseases and a putative mechanism of action for pharmacological interventions. [11C]-UCBJ positron emission tomography (PET), which quantifies synaptic vesicle glycoprotein 2A (SV2A) density, offers the most direct in vivo measure of human...

530. Detecting neuroplastic effects induced by ketamine and classic psychedelics in healthy human subjects

The International Journal of Neuropsychopharmacology September 9, 2026 Claudio Agnorelli, Joseph Peill, Danielle Kurtin et al.

Abstract Background Clinical studies have shown that ketamine and classic psychedelics can produce robust and rapid antidepressant effects after a single or a few administrations. However, the neurobiological mechanisms driving these long-lasting changes remain unclear. A leading framework proposes that both drug classes induce sustained increases in neuroplasticity, potentially reshaping...

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

Journal of Cerebral Blood Flow & Metabolism March 21, 2026 Claudio Agnorelli, Joseph Peill, Gabriela Sawicka et al.

We investigated ketamine's neuroplastic effects in healthy human subjects using integrated Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) measures before and 1-8 days after a single psychedelic dose of ketamine (1 mg/kg, intravenous). Eleven male participants underwent two PET/MRI scans with [11C]-UCBJ (synaptic density/plasticity), 1H-MRS (glutamate and GABA) and...

Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.

Psychological Medicine August 26, 2025 Michael Angyus, Sarah Osborn, Eline Haijen et al.

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

DOI: 10.1017/s0033291725101219 (opens in new tab) Full text (opens in new tab) Psychedelics Psychedelic substances Psychedelic experiences Psychedelic research +17

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Comprehensive Psychiatry July 1, 2025 Luca Pellegrini, Naomi A Fineberg, Sorcha O'Connor et al. 17 citations

Obsessive-compulsive disorder (OCD) is a common and disabling condition. A large proportion of patients fail to respond to first-line treatment with serotonin reuptake inhibitors either selective serotonin reuptake inhibitors (SSRIs) or clomipramine. Preliminary evidence suggests psilocybin, a serotonin receptor agonist, might be efficacious. We conducted a pharmacological challenge study to...

DOI: 10.1016/j.comppsych.2025.152619 (opens in new tab) Full text (opens in new tab) Compulsions Ossessive-compulsive disorder Psychedelics OCD Treatment +2

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies

Frontiers in Psychology June 6, 2025 William Roseby, Hannes Kettner, Leor Roseman et al. 6 citations

Introduction Psychedelics, such as psilocybin, are increasingly recognized for their propensity to elicit powerful subjective experiences that carry personal meaning. While research has demonstrated the capacity for these compounds to promote psychological wellbeing, it has yet to be shown to what extent they modulate "meaning in life", a specific contributor to mental and physical health....

DOI: 10.3389/fpsyg.2025.1580663 (opens in new tab) Naturalism Meaning existential Cognitive psychology Psychotherapist +3

Study Protocol for ‘PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity’

Cureus January 29, 2025 Sorcha O'Connor, Kate Godfrey, Sara Reed et al. 2 citations

This study's results are expected to offer critical insights into the neural mechanisms underlying the effects of psilocybin-assisted therapy in treating OCD, and whether these correlate with changes in the cognitive features of the condition. As a secondary aim, it will ascertain whether a low, tolerable dose is a feasible and efficacious clinical treatment, and will provide crucial data to...

Serotonergic psychedelics for depression: A comprehensive overview.

International review of neurobiology 2025 A M Wingert, Claudio Agnorelli, Joseph Peill et al. 1 citation

Depressive disorders continue to pose a major clinical challenge worldwide, particularly given the high prevalence and increasing number of treatment-resistant cases. Over the past decade, advances in research have elucidated the antidepressant potential of psilocybin and other 5-HT₂A receptor agonists in patients with major depressive disorder (MDD) and treatment-resistant depression (TRD)....

Correction: Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.

Cureus 2025 Sorcha O'Connor, Kate Godfrey, Sara Reed et al. correction

Background: Obsessive-compulsive disorder (OCD) is a complex condition marked by persistent distressing thoughts and repetitive behaviours. Despite its prevalence, the mechanisms behind OCD remain elusive, and current treatments are limited. This protocol outlines an investigative study for individuals with OCD, exploring the potential of psilocybin to improve key components of cognition...

DOI: 10.7759/cureus.c209 (opens in new tab) Full text (opens in new tab) Psychedelics Mental health Clinical research OCD

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers

Neuroscience Applied December 2, 2024 Kate Godfrey, Brandon Weiss, Joseph Peill et al. 5 citations

This study investigated the effects of a single high-dose of psilocybin on personality traits in psychedelic-naïve healthy volunteers. These data originate from a larger within-subjects fixed-order design trial, where a single high dose of psilocybin (25 mg) was administered in a psychologically supportive setting and was compared against a (one-month) prior, 1 mg 'placebo' dose. Personality...

DOI: 10.1016/j.nsa.2024.104092 (opens in new tab) Personality Clinical psychology

Validation of the imperial psychedelic predictor scale.

Psychological Medicine September 27, 2024 Michael Angyus, Sarah Osborn, Eline Haijen et al. 10 citations

Abstract Background Access to psychedelic drugs is liberalizing, yet responses are highly unpredictable. It is therefore imperative that we improve our ability to predict the nature of the acute psychedelic experience to improve safety and optimize potential therapeutic outcomes. This study sought to validate the ‘Imperial Psychedelic Predictor Scale’ (IPPS), a short, widely applicable,...

DOI: 10.1017/s0033291724002204 (opens in new tab) Full text (opens in new tab) Ego dissolution Psychedelic research Psychedelics Psychedelic studies +23

Psychedelics and the ‘inner healer’: Myth or mechanism?

Journal of Psychopharmacology April 12, 2024 Joseph Peill, Miriam Marguilho, David Erritzøe et al. 16 citations

Background: Reference to an intrinsic healing mechanism or an ‘inner healer’ is commonplace amongst psychedelic drug-using cultures. The ‘inner healer’ refers to the belief that psychedelic compounds, plants or concoctions have an intrinsically regenerative action on the mind and brain, analogous to intrinsic healing mechanisms within the physical body, for example, after sickness or injury....

DOI: 10.1177/02698811241239206 (opens in new tab) Telos Automatic Psychedelic-therapy Natural-healing +2

Psychedelics and sexual functioning: a mixed-methods study

Scientific Reports February 7, 2024 Tommaso Barba, Hannes Kettner, Caterina Radu et al. 24 citations

Abstract Do psychedelics affect sexual functioning postacutely? Anecdotal and qualitative evidence suggests they do, but this has never been formally tested. While sexual functioning and satisfaction are generally regarded as an important aspect of human wellbeing, sexual dysfunction is a common symptom of mental health disorders. It is also a common side effect of selective serotonin reuptake...

DOI: 10.1038/s41598-023-49817-4 (opens in new tab) Full text (opens in new tab) Psilocybin Escitalopram Clinical psychology Sexual dysfunction +2

Psilocybin and Other Classic Psychedelics in Depression.

Current Topics in Behavioral Neurosciences 2024 D J Nutt, Joseph Peill, B Weiss et al. 30 citations

Psychedelic drugs such as psilocybin and ketamine are returning to clinical research and intervention across several disorders including the treatment of depression. This chapter focusses on psychedelics that specifically target the 5-HT2A receptor such as psilocybin and DMT. These produce plasma-concentration related psychological effects such as hallucinations and out of body experiences,...

A Bayesian Reanalysis of a Trial of Psilocybin Versus Escitalopram for Depression

Psychedelic Medicine October 28, 2022 Bruna Giribaldi, Sandeep M. Nayak, Bilal A. Bari et al. 15 citations

Background: A trial of psilocybin (COMP360) versus escitalopram for major depressive disorder (MDD) was reported as negative, as there was no significant difference in the primary outcome, mean change in the 16-item Quick Inventory of Depressive Symptomatology–Self-Report (QIDS SR-16). However, analyses using three other depression scales (17-item Hamilton Depression Rating Scale [HAMD-17],...

Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience.

Journal of Psychopharmacology January 5, 2022 Joseph Peill, Katie Trinci, Hannes Kettner et al. 135 citations

Introduction: As their name suggests, 'psychedelic' (mind-revealing) compounds are thought to catalyse processes of psychological insight; however, few satisfactory scales exist to sample this. This study sought to develop a new scale to measure psychological insight after a psychedelic experience: the Psychological Insight Scale (PIS). Methods: The PIS is a six- to seven-item questionnaire...

DOI: 10.1177/02698811211066709 (opens in new tab) Full text (opens in new tab) Psychedelic research Psychological insight Psychometric scale Therapeutic potential